ArticleTranslational vision science & technology2026
Validation of a Machine Learning Approach to the Analysis of Multifocal Electroretinograms for Hydroxychloroquine Retinopathy.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Hydroxychloroquine (HCQ) retinopathy is detectable through multimodal ophthalmic screening, yet individual diagnostic tests each have inherent limitations. Machine learning may simplify monitoring, but few HCQ screening algorithms have undergone rigorous external validation. This study evaluated the clinical utility of the Multifocal Electroretinogram Classification Interface (MERCI) algorithm by assessing its ability to predict HCQ retinopathy compared with diagnoses derived from American Academy of Ophthalmology (AAO) guidelines. Methods: Patients referred for HCQ toxicity screening underwent perimetry, spectral-domain optical coherence tomography, fundus autofluorescence photography, and multifocal electroretinogram (mfERG) testing. Performance was assessed in a temporal dataset (participants overlapping with the development dataset) and a novel dataset (newly enrolled participants). Reference diagnoses were assigned using AAO guideline-based decision trees informed by ancillary tests results. MERCI generated corresponding mfERG-based predictions, which were compared with reference diagnoses to compute performance metrics for each dataset. Results: Using the decision trees, the temporal (n = 145) and novel (n = 300) datasets showed retinopathy prevalences of 12.4% and 9.7%, respectively. MERCI yielded 63/145 (43.4%) and 115/300 (38.3%) false-positive cases, respectively. MERCI achieved strong sensitivity (1.000 temporal; 0.931 novel) and negative predictive value (NPV) (1.000 temporal; 0.987 novel), with comparable area under the curve between datasets (0.759 temporal; 0.805 novel). Conclusions: MERCI retained high sensitivity and NPV when validated against temporally distinct cohorts using a clinical definition of HCQ toxicity. This suggests MERCI's potential as a screening tool for HCQ retinopathy. Translational Relevance: The mfERG-based machine learning models may improve screening efficiency and clinical decision-making for HCQ users.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.